Alterity Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Alterity Therapeutics (ATHE).

Price Target Range — 5 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$11Upside to Avg. PT+387.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	Lake Street	Thomas Flaten	Initiate	Buy	$10
Aug 11, 2026	Craig-Hallum	Adam Vogel	Initiate	Buy	$12
Jun 30, 2026	Jones Trading	Debanjana Chatterjee	Initiate	Buy	$16
Jun 16, 2026	Ladenburg Thalmann	Caroline Palomeque	Assumes	Buy	$10
Dec 17, 2025	Canaccord Genuity	—	Initiate	Speculative Buy	—
Jan 30, 2025	Maxim Group	Jason McCarthy	PT Raise	Buy	$8→$12
Dec 12, 2024	Maxim Group	Jason McCarthy	Initiate	Buy	$8
Mar 7, 2024	Benchmark	Robert Wasserman	Maintained	Speculative Buy	$4

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10

Lake Street analyst Thomas Flaten initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $16.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

Maxim Group analyst Jason McCarthy maintains Alterity Therapeutics (NASDAQ:ATHE) with a Buy and raises the price target from $8 to $12.

Benzinga Newsdesk

PRO
Maxim Group Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $8

Maxim Group analyst Jason McCarthy initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

Alterity Up on Interim Data From Advance MSA Study

Shares of Alterity Therapeutics (NASDAQ: ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy, a rare neurodegenerative disease.

Zacks

Alterity Therapeutics Ltd

ニュース

パートナーシップ

ベンジンガ・グローバル

Alterity Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10

PRO
Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

PRO
Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

PRO
Maxim Group Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $8

Alterity Up on Interim Data From Advance MSA Study

People Also Watch

People Also Watch

Alterity Therapeutics Ltd

ニュース

パートナーシップ

ベンジンガ・グローバル

Alterity Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10

PROCraig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

PROJones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

PROMaxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

PROMaxim Group Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $8

Alterity Up on Interim Data From Advance MSA Study

People Also Watch

People Also Watch

PRO
Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10

PRO
Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16

PRO
Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

PRO
Maxim Group Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $8